Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Good Girl Rx vs Maves

Good Girl Rx
Graded #251

Lower grade

vs+7.899999999999999
Maves
Graded #88

Higher grade

The verdict

Maves takes it — 71.8/100 to 63.9/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +41
43
84
Dose & formulationGood Girl Rx +23
88
65
Clinical oversightGood Girl Rx +5
81
76
Labs & monitoringEven
52
52
FulfillmentMaves +18
69
87
Contract termsMaves +14
41
55
Good Girl Rx · left barMaves · right bar

The numbers

MetricGood Girl RxMaves
WeighScore63.9/10071.8/100
GradeCC
Scorecard rank#251#88
Semaglutide$134/mo (starting dose, annual plan, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$235/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
Good Girl Rx

Graded #251 · C

Strengths

  • LegitScript certified
  • Multiple formats — injectable, microdose, and ODT pills — for both semaglutide and tirzepatide
  • Dispensed by licensed 503A or 503B pharmacies
  • Limited brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • Named legal entity with a Nashville address

Where it loses points

  • State availability not disclosed
  • Very new brand — founded January 2025
  • Celebrity-founded (Savannah Chrisley) — brand vs clinical credibility
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard